TITAX AMI: A prospective, multicenter, randomized trial comparing B.A.S (Titan2) to D.E.S (Taxus) for acute myocardial infarction

TCT 2008, Karjalainen et al.
The aim of this randomized trial was to compare the clinical outcome of patients presenting Myocardial Infarction treated by PCI either with a Bio Active Stent (BAS) coated with Titanium-NO or a Paclitaxel Eluting Stents (PES).
View document (pdf file, 315Kb)

SIRTAX II: BAS (Titan2) vs SES (Cypher) vs PES (Taxus), a 12-month follow-up

TCT 2007, Windecker et al.
The aim of this registry was to compare the clinical outcomes of patients treated by P.C.I and receiving either a BAS, a SES or a PES in a population without exclusion criteria.
View document (pdf file, 670Kb)

TITAX 12 months: A prospective, multicenter, randomized trial comparing B.A.S (Titan2) to D.E.S (Taxus) for acute myocardial infarction

TCT 2007, Karjalainen et al.
The aim of this randomized trial was to compare the clinical outcome of patients presenting Myocardial Infarction treated by PCI either with a Bio Active Stent (BAS) coated with Titanium-NO or a Paclitaxel Eluting Stents (PES).
View document (pdf file, 168Kb)

TITAX 6 months: A prospective, multicenter, randomized trial comparing B.A.S (Titan2) to D.E.S (Taxus) for acute myocardial infarction

PCR 2007, Karjalainen et al.
The aim of this randomized trial was to compare the clinical outcome of patients presenting Myocardial Infarction treated by PCI either with a Bio Active Stent (BAS) coated with Titanium-NO or a Paclitaxel Eluting Stents (PES).
View document (pdf file, 808Kb)

PORI Registry: A 36-month follow-up
(BAS vs PES vs BMS)

PCIC 2007, Karjalainen et al.
To compare clinical outcomes of Titanium-Nitride-Oxide Coated Stents, Paclitaxel Eluting Stents and Bare Metal Stents in routine clinical practice.
View document (pdf file, 441Kb)

Randomized study comparing stainless steel with Titanium-Nitride-Oxide coated stents for coronary artery lesions

SOLACI 2006, Fernando Mendes Sant'Anna
The aim of this prospective and randomized study is to assess the safety and efficacy of the TiTAN2 stent versus BMS and to compare the rate of Major Adverse Cardiac Events (MACE). Titanium-Nitride-Oxide coated stents have shown efficacy to reduce neointimal hyperplasia in comparison to conventional stents both in animals and human beings.
View document (pdf file, 171Kb)

PORI Registry: A 12-month follow-up
(BAS vs PES vs BMS)

TCT 2006, Karjalainen et al.
To compare clinical outcomes after implantation of Titanium-Nitride-Oxide Coated Stents, Paclitaxel Eluting Stents or Bare Metal Stents in an Unselected Population.
View document (pdf file, 1004Kb)

Randomized trial of a Titanium-NO coated stents vs bare metal stents in acute coronary syndromes: early and late thrombosis and restenosis

CFCI 2005, Sansa et al.
The purpose of this randomized study was to evaluate the efficacy of a Titanium-NO coated stent versus bare metal stents (BMS) on early and late thrombosis as well as on angiographic restenosis in a group of patients with either unstable angina or acute myocardial infarction (AMI) undergoing percutaneous Coronary Intervention.
View document (pdf file, 294Kb)

TINOX Trial: Randomized comparison of a Titanium-Nitride-Oxide coated stent with a stainless steel stent for coronary revascularisation

Circulation 2005
Stent coating with titanium-nitride-oxide has been shown to reduce neointimal hyperplasia in the porcine restenosis model. TINOX Trial is a prospective, randomized, clinical study to investigate the safety and efficacy of titanium-nitride-oxide coated stents compared with stainless steel stents of similar design.
View document (pdf file, 561Kb)

Real world experience in treating patients with TITAN stent: A 9-month follow-up report from the TITAN PORI Registry

TCT 2005, Karjalainen et al.
The aim of the Titan PORI registry was to evaluate the clinical safety and efficacy of a stainless steel stent covered with Titanium and Nitride Oxide (Titan, Hexacath, France) in routine clinical practice.
View document (pdf file, 771Kb)

The Titanium-NO stent in real world: Results from a multi-center registry

TCT 2005, Mosseri et al.
Five to 15% of the population have allergy to nickel, chromium or molybdenum which is a potential cause for in-stent restenosis. The Titan stent is made of stainless steel and coated with Titanium Nitride Oxide (TiNOX) which completely prevents discharge of metal elements. A double blinded controlled study has shown that TiNOX stent reduces restenosis and MACE. However, Cardiogenic shock patients were excluded from this study. Therefore, we performed a real life multi-center registry to assess short and long term results of the Titan stent.
View document (pdf file, 56Kb)

The TITAN stent: Data from a national registry

TCT 2004, Mosseri et al.
Five to fifteen percent of the population have an allergy to nickel, chromium or molybdenum, which may be responsible for inducing restenosis. The Titan stent is made of stainless steel and is coated with titanium-nitride oxide (TiNOX), which completely prevents the discharge of metal elements. We performed a real-life multicenter registry to assess the short- and long-term characteristics of the Titan stent.
View document (pdf file, 60Kb)

The TIBET study: Multicenter Titan Registry in the treatment of coronary lesions in diabetic patients

TCT 2004, Valdès et al.
Stents coated with Rapamycine and Paclitaxel have shown efficacy in reducing restenosis and cardiac events. Diabetics have one of the highest restenosis rate after PTCA. Despite results obtained with stents coated with Rapamycine and Paclitaxel in diabetic patients, results with other sort of coated slents are not well known. The TIBET registry is a multicenter study to document diabetic patients with De Novo lesions treated by PTCA with a Titan coronary stent.
View document (pdf file, 433Kb)